Hospira To Double Sales Force In Japan
This article was originally published in PharmAsia News
Executive Summary
Osaka-based Hospira Japan will further expand in the Japanese generics market in the near future
|
Osaka-based Hospira Japan will further expand in the Japanese generics market in the near future. To prepare for the expansion, the company has decided to increase medical sales reps from 40 to 100 in five years. Last November, Hospira launched four oncology products in Japan, irinotecan in 40 mg and 100 mg and gemcitabine 200mg and 1g. These intravenous injections were contained inside Hospira proprietary ONCO-TAIN containers, which prevent damage and contaminations. (Click here for more - Japanese language) "Hospira To Double MRs To Focus In Japanese Market" - Nikkei Sangyo News (3/4/2011) |